Osteoporosis has been called as a silent epidemic, characterized by reduced bone mineral density (BMD) and deterioration of bone micro-architecture that leads to enhanced bone fragility and increased risk of fracture.^[@bib1]^ The problem of this disease in India is even more alarming as 61 million people suffer from this disease. Therefore, formation of bone is the ultimate strategy that one aims for the treatment of disease like osteoporosis.^[@bib1]^ The major cause of post-menopausal osteoporosis is deficiency of female steroid hormone estrogen. Both men and women start losing bones after the age of 40 years but the rate of loss is faster in women due to menopause. Subsequently, the incidence of bone fractures is two- to threefold high in women as compared with men.^[@bib2]^

FDA-approved drugs for osteoporosis fall into two categories: the anabolic. which induce osteoblast formation such as parathyroid hormone (PTH),^[@bib3]^ and anti-resorptive drugs, which inhibit osteoclast function such as bisphosphonates, estrogen and estrogen analogs.^[@bib4],\ [@bib5]^ PTH (teriparatide) has exhibited promising results with doubled the rate of bone formation, reduced (60--70%) vertebral fracture and reduction in the risk of non-vertebral fractures by about ∼50%. However, PTH has shown black box warning of osteosarcoma in small animals.^[@bib6]^ For anti-resorptive raloxifene, the only SERMs are currently approved for osteoporosis that reduces spine fractures.^[@bib7]^ It also reduces the risk of hormone-positive breast cancer,^[@bib8]^ but its effect on cardiovascular disease remains uncertain.^[@bib9]^ Alendronate (ALN) increased the formation of fibroblastic colonies in cultures of rat bone marrow.^[@bib10]^ Combination therapy of PTH with ALN have shown synergistic effect on BMD, which is not fully supported by some observational studies.^[@bib11],\ [@bib12]^ With available literature, further investigation is needed on the long-term risks, benefits of these drugs and development of novel therapies.

The aim of this study was to investigate alternative anabolic drugs for the treatment of osteoporosis. We have identified a novel isoflavone glucoside, caviunin 7-O-\[*β*-[D]{.smallcaps}-apiofuranosyl-(1--6)-*β*-[D]{.smallcaps}-glucopyranoside\] that has been abbreviated as CAFG, which is extracted from leaves of *Dalbergia sissoo Roxb.*^[@bib13]^ It belongs to the legume family (Fabaceae).^[@bib14]^ Here we show that this potent flavonoid could act like a bioactive molecule and could counteract the deleterious effects of estrogen deficiency occurring during menopause in women. CAFG\'s potential to induce osteogenesis was measured biochemically by assessing the activity of alkaline phosphatase (ALP) and then mineralization.^[@bib13]^ Overall, data show that CAFG, a novel isoflavonoid, enhanced osteogenic activity more and at much lower doses as compared with its structural analog genistein. Interestingly, CAFG is not estrogenic, instead promoted osteoblastic differentiation by activating the bone morphogenetic protein 2 (BMP2)-Wnt/*β*-catenin signaling pathway. We also show that CAFG modulates the cortical bone repair process after drill-hole injury by enhancing the function and differentiation of osteoblast.

Results
=======

Dose determination of CAFG
--------------------------

[Figure 1a](#fig1){ref-type="fig"} shows the structural differences between CAFG (MW=668), caviunin (MW=374.34) and genistein (MW=270.2). Basic skeleton of the molecules is the glycine isoflavone; however, CAFG additionally contains two sugar moieties attached to it.^[@bib13]^ Dose validation by subcutaneously injecting CAFG at doses of 0.5, 1.0, 5.0 and 10 mg/kg body weight for 3 consecutive days shows increased expression for osteogenic genes (ALP, Runt-related transcription factor 2 (Runx2) and collagen type 1 (COL1), [Figure 1b](#fig1){ref-type="fig"}) at both 1.0 and 5.0 mg/kg dose with no stimulation at either low dose of 0.5 mg/kg or highest dose of 10 mg/kg. Therefore, further experiments were carried out at doses of 1 and 5 mg/kg of CAFG.

CAFG prevents bone loss in estrogen deficiency model and improves biomechanical strength
----------------------------------------------------------------------------------------

Oral administration of CAFG shows its appearance in blood after 3.0±0.5 h with a maximum concentration (Cmax) of 160.23 ng/ml. The drug showed AUC value of 1528.91±107ngxh/ml showing rapid absorption (data not shown).

Data of isolated bones by three-dimensional (3D)-*μ*CT show that 6 weeks of ovariectomy (OVx; estrogen withdrawal) induced deterioration of the trabecular micro-architecture owing to destruction of the trabecular bone in the tibia proximal region ([Figure 1d](#fig1){ref-type="fig"}), femur epiphysis and Lumber-5 (L-5) vertebrae ([Supplementary Data](#sup1){ref-type="supplementary-material"}). Treatment with CAFG and GEN at 1 and 5 mg/kg dose exhibited well-developed trabeculae, comparable to the control Sham+vehicle and standards PTH, ALN. Quantification of these data at the tibial proximal sites shows significantly increased bone volume/tissue volume (BV/TV; [Figure 1e](#fig1){ref-type="fig"}), trabecular thickness (Tb.Th; [Figure 1f](#fig1){ref-type="fig"}), trabecular number (Tb.No; [Figure 1g](#fig1){ref-type="fig"}) and decreased trabecular separation (Tb.Sp.; [Figure 1h](#fig1){ref-type="fig"}) and structural model index (SMI; [Figure 1i](#fig1){ref-type="fig"}), as compared with OVx+vehicle group that had significantly reduced (−80%) BV/TV, Tb.No, Tb.Th and increased Tb.Sp. and SMI. Inter-dose comparisons show that 1 mg/kg dose was more effective in increasing BV/TV (*P*\<0.05) as compared with the 5 mg/kg dose. Overall, data suggest that 1 mg/kg oral dose of CAFG and 5 mg/kg of GEN for 6 weeks treatment were effective enough for more robust changes as compared with other doses of CAFG or GEN. CAFG could not surpass the positive effects as achieved by either PTH or ALN on bone but it showed comparable response.

Biomechanical strength data showed that CAFG dose dependently, especially 1 mg/kg dose in femur mid-diaphysis region, that is, cortical region of bone, increased femur breaking strength and energy *versus* the OVx group (*P*\<0.001, *P*\<0.01) ([Table 1](#tbl1){ref-type="table"}) and increased L-5 stiffness and energy when compared with all other groups that were comparable to PTH and ALN ([Table 1](#tbl1){ref-type="table"}).

CAFG induced new bone formation in mice
---------------------------------------

Parameters of new bone formation, mineral apposition rate (MAR)^[@bib15]^ and bone formation rate (BFR)^[@bib15]^ over unit bone surface area (BFR/BS) were reduced to ∼65% in OVx mice compared with the Sham group (*P*\<0.001) as in [Table 1](#tbl1){ref-type="table"}. CAFG, GEN and PTH treatment for 6 weeks increased BFR/BS in OVx mice ([Figure 1j](#fig1){ref-type="fig"}). Inter-dose comparisons within group shows that 1 mg dose of CAFG increased bone formation to ∼65% more *versus* the OVx group and ∼13% more than CAFG (5 mg dose). As compared with 1 mg/kg dose of GEN, double the amount of BFR/BS was achieved with CAFG at 1 mg/kg ([Table 1](#tbl1){ref-type="table"}).

CAFG treatment reduces bone turnover markers in OVx mice
--------------------------------------------------------

OVx-induced bone loss was characterized by higher bone turnover rates, as represented by higher levels of ∼33% of serum Osteocalcin (OCN) compared with the Sham group ([Figure 1k](#fig1){ref-type="fig"}).^[@bib16]^ However, 6 weeks of CAFG treatment to OVx group significantly lowered back the levels of this marker to ∼30%, indicating attenuation of bone turnover and thus resorption. CAFG (1 mg/kg/day) was more effective in lowering down the serum OCN levels as compared with GEN (*P*\<0.05; [Figure 1k](#fig1){ref-type="fig"}).

CAFG elicits no uterine estrogenicity
-------------------------------------

OVx resulted in reduction in all uterine parameter (wet uterine weight, luminal area and epithelial cell height), which is shown in [Figure 1l.](#fig1){ref-type="fig"}^[@bib17],\ [@bib18]^ These mice on treatment with either 1 or 5 mg/kg/day dose of CAFG, GEN, PTH and ALN for 6 weeks exhibited no change in uterine weight indicating no hyperplasic effect compared with OVx ([Table 1](#tbl1){ref-type="table"}).

Bone marrow cells (BMCs) after treatment with CAFG induced cell proliferation, differentiation and mineralization
-----------------------------------------------------------------------------------------------------------------

CAFG increased cell proliferation at 1.0 mg/kg/day (*P*\<0.001) and GEN at 5.0 mg/kg/day (*P*\<0.01) compared with OVx group ([Figure 2c](#fig2){ref-type="fig"}) assessed by 5-Bromo-2′-deoxyuridine (BrdU) assay. The measurement of cell viability and proliferation of treated BMCs revealed that all treated compound has more cell proliferation compared with OVx group ([Figure 2c](#fig2){ref-type="fig"}). For further experiments, 1 mg/kg/day dose for CAFG and 5 mg/kg/day dose of GEN were used. [Figure 2a](#fig2){ref-type="fig"} shows that BMCs from the OVx group resulting in ∼30% decreased differentiation of BMCs toward osteogenic line as seen by ALP assay. CAFG at 1 mg/kg/day (*P*\<0.001) and 5 mg/kg/day(*P*\<0.01) doses significantly promoted differentiation of BMCs toward osteoblast with maximum stimulation at 1 mg/kg/day dose (∼60%) Comparison with GEN, PTH and ALN shows that CAFG stimulates differentiation of cells comparable to the sham ([Figure 2a](#fig2){ref-type="fig"}). Data were corroborated by mineralization assay ([Figure 2b](#fig2){ref-type="fig"} upper panel).

CAFG increased expression of osteogenic genes with decreased expression of osteoclastogenic genes in long bones
---------------------------------------------------------------------------------------------------------------

CAFG significantly (*P*\<0.01) increased the expression of osteogenic genes, osteoprotegerin (OPG, [Figure 2d)](#fig2){ref-type="fig"} and *OCN* gene ([Figure 2e)](#fig2){ref-type="fig"}. Analysis of expression of resorption marker gene shows that OVx resulted in increased expression of RANKL (receptor activator of nuclear factor kappaB ligand), TRAP (tartrate-resistant acid phosphatase) and RANK (receptor activator of nuclear factor kappaB). Whereas the expression was reduced by CAFG at 1 mg/kg/day, GEN at 5 mg/kg/day, PTH and ALN ([Figures 2f and g](#fig2){ref-type="fig"}) up to Sham.

CAFG decreases enhanced resorption in ovariectomized mice
---------------------------------------------------------

TRAP staining of decalcified tibia bone revealed a massive increase in osteoclast number (Oc/Bs) and osteoclast surface (Os/Bs) in OVx group, which significantly recovered after treatment with CAFG and GEN. CAFG at 1 mg/kg/day dose has decreased osteoclast number (*P*\<0.01) and osteoclast surface area (*P*\<0.01), which is comparable to positive control groups ([Figures 2h--j](#fig2){ref-type="fig"}).

CAFG promoted extracellular matrix synthesis *in vitro*
-------------------------------------------------------

We have examined the ability of CAFG to modulate chondrogenesis in this experiment. CAFG induce proliferation of chondrocytes at day 2, but by day 4, proliferation increased at 1.0 *μ*M concentration of CAFG, with the highest being at 10 nM (*P*\<0.001) as assessed by using MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) in articular chondrocytes from newborn mice pups (1- to 2-day old)^[@bib19]^ ([Figure 3a](#fig3){ref-type="fig"}). At 100 pM or 1.0 pM, increase in proliferation was plateau off. Overall, CAFG was not toxic to the chondrocytes. Estimation of the chondrogenic effect was done by micro-mass culture. Alcian blue staining specific for chondrocytes ([Figure 3b](#fig3){ref-type="fig"}) shows that with CAFG treatment at 1.0 *μ*M and 10 nM there is a greater deposition of proteoglycans and increased chondrogenic activity by day 14, whereas by day 7, there are no changes in the cells ([Figure 3b](#fig3){ref-type="fig"}). Quantitative real-time PCR (Q-PCR) assessment of cartilage-specific genes Sox9 (early chondrogenic marker),^[@bib20]^ aggrecan (cartilage-specific proteoglycan core protein)^[@bib21]^ and Runx2 (proliferates chondrocytes),^[@bib22]^ at days 7 and 14 post CAFG treatment shows that 10 nM concentration significantly increased the expression of all the three genes as compared with the 1.0 *μ*M concentration ([Figure 3c](#fig3){ref-type="fig"}). Data were further corroborated at the protein level for Sox9 and Runx2 ([Figure 3d](#fig3){ref-type="fig"}). Overall, *in vitro* data imply that CAFG is an effective accelerant for chondrogenesis, which was further tested in the *in vivo* system.

CAFG accelerated repair of cortical bone after drill-hole injury in mouse
-------------------------------------------------------------------------

Our *in vitro* data in chondrocytes suggested that CAFG could have a potential in fracture healing. Therefore, doses of 1 and 5 mg/kg/day were tested in the drill hole as shown in [Figure 4a](#fig4){ref-type="fig"}. For confirmation of osteoporotic bone before generation of drill-hole defect, micro-computed tomography (*μ*-CT) was performed^[@bib23]^ that shows that OVx mice have less trabecular bone, disorganized trabecular structure and thinning of cortical bones compared with Sham mice (data shown in [Table 2](#tbl2){ref-type="table"}). CAFG treatment at doses of 1 and 5 mg/kg/day increased mineral deposition (measured from the intensity of calcein labeling in the drill hole; [Figures 4b and c](#fig4){ref-type="fig"}) as early as 11th day post fracture as compared with controls (day 0; [Figure 4c](#fig4){ref-type="fig"}). The OVx group with drill hole showed the same effect in response to CAFG treatment but bone formation was significantly less when compared with Sham group ([Figure 4c)](#fig4){ref-type="fig"}. Data were verified by *μ*-CT of drill-hole area ([Figure 4d](#fig4){ref-type="fig"}), which showed 2D and 3D images generated by *μ*-CT with increased BV/TV and Tb.No and decreased Tb.Sp. and SMI evidenced by significantly more callus being formed in the drill hole after CAFG treatment as early as on day 11th ([Figures 4e and f](#fig4){ref-type="fig"}). It led to predominantly occupied mineralized callus, and the defect region was partially bridged in the Sham groups. But as compared with the 5 mg/kg/ day, 1 mg/kg/day had significantly more effect. Rate of callus formation of Sham group *versus* the OVx group shows that OVx mice had lower mineral deposition (39.0% less) than the Sham group; however, within the OVx group, CAFG at both the doses of 1 and 5 mg/kg/day increased mineral deposition. Results were consistent with Q-PCR data with increased expression of osteogenic genes *Runx2*, *BMP2*, *BMP4*, *OCN* and COL1 mRNA ([Figure 4g](#fig4){ref-type="fig"}). Expression of genes peaked significantly with 1 mg/kg/day on day 11 as compared with the 5 mg/kg/day dose. Increased mRNA expression of OCN was complimented with the increased serum levels of OCN ([Figure 4h)](#fig4){ref-type="fig"}. Overall, CAFG significantly contributed to the healing process in bone as observed in both Sham and OVx group.

CAFG reduces apoptosis of osteoblast cells
------------------------------------------

Data of fluorescence-activated cell sorting (FACS) following Annexin-V/PI staining ([Figure 5a](#fig5){ref-type="fig"}) show that CAFG treatment to these cells attenuated the number of apoptotic cells to ∼4% ([Figure 5b](#fig5){ref-type="fig"}) compared with 12% apoptotic cells in 0.5% FCS. Data also suggest that CAFG has the ability to rescue cells undergoing early apoptosis as compared with the cells that are late apoptotic or have become necrotic.

Effects of CAFG on p38 mitogen-activated protein kinase (MAPK) activation and BMP2 secretion in osteoblasts
-----------------------------------------------------------------------------------------------------------

CAFG stimulated osteoblast differentiation by increasing ALP production ([Figure 5c](#fig5){ref-type="fig"}). This ALP activity was completely inhibited by p-38 MAPK inhibitor SB203580. Consistent with the observation that SB203580 blocked CAFG-induced ALP activity in osteoblast. CAFG stimulated phosphorylation of p-38 MAPK as early as at 12 h and attaining peak phosphorylation at 24 h ([Figure 5d](#fig5){ref-type="fig"}), these findings were corroborated by western blot analysis at the same time points ([Figure 5e](#fig5){ref-type="fig"}). CAFG increased BMP2 expression, a potent stimulator of osteogenesis in time-dependent manner with the maximum stimulation being at 24 h ([Figure 5f](#fig5){ref-type="fig"}). CAFG-induced BMP2 expression was inhibited in the presence of noggin (an endogenous BMP2 antagonist) at mRNA, protein and secreted BMP2 levels in conditioned media ([Figures 5g--i](#fig5){ref-type="fig"}). Assessment of BMP2-dependent genes in the presence of CAFG shows that Smad1 and ALP expression levels were abrogated by noggin in mice calvarial osteoblast cells ([Figure 5j](#fig5){ref-type="fig"}), indicating that CAFG-induced Smad-1 phosphorylation ([Figure 5l](#fig5){ref-type="fig"}) is BMP2 dependent. Further, since BMP function activates Smad-1 proteins to stimulate expression of target gene *Runx2*. We used mouse full-length dual luciferase reporter system to test the effects on osteogenic differentiation in response to CAFG ([Figure 5k](#fig5){ref-type="fig"}). Our data show that CAFG induced the osteogenic activity as early as 6 h by activation of pRunx2-Luc promoter of osteoblast in time-dependent manner that was maintained upto 24 h as evident also at protein level ([Figures 5k and l](#fig5){ref-type="fig"}). To prove that CAFG stimulation is dependent on MAPK activation, we checked BMP2 expression in the presence of SB203580 that significantly attenuated the CAFG-induced increase in BMP2 expression from osteoblast ([Figure 5m](#fig5){ref-type="fig"}), suggesting that MAPK activation is a prior event than BMP2 expression. Together, data presented demonstrate that CAFG induces BMP2 secretion via the p-38 MAPK pathway in osteoblasts and the resultant increase in the secreted BMP2 in turn may lead to osteoblast differentiation in a para/autocrine manner.

CAFG induced osteoblastic protein via canocincal Wnt/*β*-catenin signaling
--------------------------------------------------------------------------

Evidences suggest that Wnt signaling pathway modulates differentiation, proliferation and mineralization in bone formation as a downstream of BMP.^[@bib24],\ [@bib25]^ CAFG at 10 nM concentration significantly induced the expression of Wnt3a, Lrp5, GSK3*β* and *β*-catenin and significantly attenuated the expression of Dkk1, sclerostin and phosphorylated GSK3*β* levels in cultured osteoblast cells ([Figure 6a](#fig6){ref-type="fig"}). The above results were corroborated by expression seen at the protein level and quantitation of the same by densitometric analysis ([Figures 6b and c](#fig6){ref-type="fig"}). Fluorescence labeling data show that CAFG-induced nuclear localization of *β*-catenin required for transcription of target genes. BMP inhibitor noggin alone or in the presence of CAFG (increased when compared with noggin alone) blocked CAFG-induced nuclear localization of *β*-catenin in osteoblast cells, implying that BMPs mediate the nuclear localization of *β*-catenin induced by CAFG ([Figure 6d](#fig6){ref-type="fig"}). Nuclear localization of *β*-catenin was quantified by western blot analysis ([Figure 6e](#fig6){ref-type="fig"}) showing that nuclear/cytoplasmic ratio was significantly higher with CAFG treatment as compared with that of noggin alone or CAFG+noggin treatment ([Figure 6f](#fig6){ref-type="fig"}). Osteoblasogenesis by CAFG through activation of *β*-catenin/Wnt signaling was confirmed by blocking it by exogenous addition of recombinant Dkk1 ([Figures 6g--i](#fig6){ref-type="fig"}). Another small-molecule inhibitor FH535, of *β*-catenin/TCF complex formation treatment for 24 h shows that FH535 resulted in 60--70% inhibition of Wnt3a, BMP2 and *β*-catenin protein expression ([Figures 6j--l](#fig6){ref-type="fig"}). These results suggest that FH535 effectively repressed transcriptional and translational activity of *β*-catenin and therefore its downstream targets. Further, as a consequence of activation of *β*-catenin signaling and its stabilization, it increased TCF-based reporter gene activity ([Figure 6m](#fig6){ref-type="fig"}). This increased activity and expression of Wnt-responsive genes strongly support the mechanism for CAFG mediated by the BMP2-Wnt/*β* catenin signaling pathway.

Direct effect of CAFG on osteoclast cells
-----------------------------------------

CAFG at 10 nM concentration inhibited multinucleated TRAP-positive cells in BMCs as represented in [Figures 7a and b. Q](#fig7){ref-type="fig"}-PCR data show that addition of CAFG (10 nM) to differentiated osteoclasts significantly downregulated the expression of TRAP (*P*\<0.01) and RANK (*P*\<0.05) mRNA expression levels ([Figure 7c](#fig7){ref-type="fig"}). Protein data corroborated the TRAP mRNA levels that were significantly downregulated as quantified by densitometry analysis ([Figures 7d and e](#fig7){ref-type="fig"}). Altogether, data show that CAFG inhibited osteoclastogenesis of murine BMCs by inhibiting their differentiation and maturation.^[@bib26]^

Discussion
==========

Our previous study demonstrated that osteogenic effects imparted by the extract of *Dalbergia sissoo* in the estrogen withdrawal osteoporotic model were due to the presence of a novel analog CAFG present in maximum amount. We confirm that CAFG\'s ability to act as a dual acting compound stimulates osteoblast proliferation, survival and differentiation, simultaneously inhibits osteoclast formation and their differentiation in bone, suggesting positive skeletal effect.

*In vivo* CAFG has osteogenic effect in adult ovariectomized mice. Under the circumstance of estrogen-dependent skeletal growth, CAFG treatment resulted in dose-dependent increase in differentiation of osteoprogenitor cells and mineralization of BMCs, expected to favor bone formation.^[@bib27]^ As a result, we observed increased MAR and BFR (resulting from expansion of bone marrow osteoblast pool) by dynamic histomorphometry in diaphysis femur of CAFG-treated mice. In agreement with dynamic histomorphometry data, *μ*-CT (static histomorphometry) demonstrated increased trabecular bone gain by CAFG during the course of skeletal growth in mice compared with controls. Further, increased femoral periosteal bone deposition by CAFG had functional consequence in increasing bone biomechanical strength as CAFG dose-dependently increased femoral and vertebral force and stiffness. To understand detailed regulation of bone resorption, we assessed osteoclastogenesis from BMCs and bone. OVx resulted in increased resorption as seen by increased osteoclast number and activity characterizes postmenopausal bone loss. CAFG reduces the differentiation of osteoclasts around the bone surface and *in vitro* from BMCs comparable to Sham. Together, our data so far suggest that CAFG that lack uterine estrogenic effect stimulates bone formation *in vivo,* thus facilitating skeletal growth and acts as a dual acting compound, as it stimulates bone formation as well as inhibits bone resorption as evident by high expression of OPG and low expression of RANKL in treated group\'s bone marrow osteoblast cells.

CAFG has anabolic role in bone formation and primary osteoporosis in female mice. Fracture healing is a complex process and osteoporotic bone has been reported for recurrent fracture. Fracture repair includes chondrogenesis and intra-membranous ossification.^[@bib28],\ [@bib29]^ Therefore, we studied the effect of CAFG on chondrocyte cells to see whether it also affected the bone-healing process. CAFG at 10 nM concentration was not toxic and increased the proliferation of chondrocyte cells by inducing expression of BMP2, SOX9 and aggrecan sequentially and then promote the synthesis of proteoglycan of chondrocyte and thus chondrogenesis.[@bib30], [@bib31], [@bib32] CAFG enhanced biosynthetic activities and cartilage-specific gene expression, indicating that CAFG may be a potential promoting compound for cartilage-induced injury-like fracture or tissue engineering.

As drill-hole injury model of long bone seems suitable for analyzing the healing process quantitatively and investigating chondrocyte differentiation *in vivo.*^[@bib23],\ [@bib33],\ [@bib34]^ Our data, by fluorochrome labeling, show that bone regeneration in the drill hole was diminished in OVx mice, compared with Sham-operated group, which could be due to the reduced osteoblast function under estrogen deficiency. The same study showed that CAFG treatment of either Sham or OVx mice significantly augmented the process of filling up by newly generated bone in the drill hole. This finding was complemented by several *μ*-CT parameters (BV/TV, Tb.Th, Tb.No., Tb.Sp. and SMI) that indicated a more compact assembly and preferred plate-like structure (low SMI) of the newly formed bone of CAFG-treated mice. Overall, these data indicate that CAFG accelerates the bone-healing process after injury of long bones.

To specifically know the molecular target of CAFG, we next characterized the cellular signaling events being activated by CAFG. CAFG triggers BMP2-canonicalWnt/*β*-catenin signaling in osteoblasts that resulted in the stimulation of osteoblast differentiation and mineralization. Although BMP2 signaling component is distinct from the known Wnt/*β*-catenin signal transduction pathway, they may stimulate processes that cooperate with activated *β*-catenin to promote osteoblast differentiation.^[@bib24],\ [@bib35]^ The ultimate outcome of the Wnt activation after treatment with CAFG resulted in the following sequence of events: increase of *β*-catenin nuclear translocation, and as Wnt activation is highly dependent on essential osteogenic transcription factor Runx2, we found activation of Runx2 promoter. The effect of CAFG was blocked by Dkk1, a blocker of Wnt/*β*-catenin receptor and FH535 inhibitor of *β*-catenin-TCF /LEF complex. Inhibition of *β*-catenin-TCF/LEF complex almost inhibited CAFG-induced BMP2 expression suggesting interdependence of the two signaling pathways. The effect of CAFG on signaling, function and gene expression of osteoblasts leading to possible anabolic action and anti-osteoclastogenic effect is shown in [Figure 8](#fig8){ref-type="fig"}. The end result of this orchestrated activity improved BMD and biomechanical properties.

Impetus to this data, we can conclude that CAFG has ability to impart osteogenic effect at much lower dose through BMP2-canonical/Wnt/*β*-catenin signaling. The human equivalent dose of CAFG translates into ∼0.081 mg/kg/day body weight. Therefore, for a 60-kg person, the daily requirement for CAFG is calculated to be ∼4.8 mg, which is easily achievable. Moreover, CAFG devoid of uterine estrogenicity and has pronounced effect on fracture healing. Therefore, its positioning as fracture healing and anti-osteoporotic agent is alluring.

Materials and Methods
=====================

Reagents and chemicals
----------------------

Cell culture media and supplements were purchased from Sigma-Aldrich (St. Louis, MO, USA). Human PTH (1--34) was purchased from Calbiochem (Pacific Center Ct, San Diego, CA, USA) and ALN was purchased from Sigma. All fine chemicals and inhibitors (SB203580, and Noggin) were purchased from Sigma-Aldrich. Dkk1 Recombinant exogenous protein was purchased from R&D systems (Minneapolis, MN, USA), FH535 (2,5-Dichloro-*N*-(2-methyl-4-nitrophenyl)benzenesulfonamide) was purchased from Tocris Bioscience (Moorend Farm Avenue, Bristol, UK) and p38 MAP Kinase ELISA kit was purchased from Cell Signaling Technologies (Danvers, MA, USA). BMP2 ELISA was purchased from R&D systems. ECL kit was purchased from GE Healthcare Bio-Sciences (Pittsburgh, PA, USA). Antibody was purchased from Abcam (Cambridge Science Park, Cambridge, UK).^[@bib36],\ [@bib37]^

Mice calvarial cell culture
---------------------------

For each experiment, 1- to 2-day-old mice calvarial cells were used to harvest 10--20 calvarias at room temperature. Briefly, individual calvaria was surgically isolated from the skull, sutures were segregated and adherent tissue material was cleaned by gentle scrapping. As described previously,^[@bib36]^ the pooled calvarias were kept for repeated digestion (15 min/digestion) with 0.05% trypsin and 0.1% collagenase P to release cells. First digestion was discarded and cell was collected from next four digestions. Cells were cultured in a modified essential medium (*α*-MEM) containing 10% fetal calf serum (FCS) and 1% penicillin/streptomycin (complete growth medium). MCOs were allowed to reach 70--80% confluence for the experiments.

Animal
------

All animal care and experimental procedures were approved by the Institutional Animal Ethics Committee. Female balb/c mice (18±5 g) were obtained from the National Laboratory Animal Centre. Animals were kept in a 12-h light--dark cycle, with controlled temperature (22--24 °C) and humidity (50--60%) and free access to standard rodent food and water.^[@bib36]^

Cell proliferation assay
------------------------

We assayed cell proliferation by using BrdU incorporation assay. BMCs of treated groups were seeded on 96 well plates to differentiate towards osteogenic lineage. After differentiation, cells were kept for 24 h to arrest growth with serum-free media. BrdU (10 ng/ml) was added to the media. Then the cells were incubated for 4 h. The cells were washed, fixated and then stained with the BrdU antibody by using a BrdU staining kit (Roche Applied Sciences, Branford, CT, USA) following the manufacturer\'s instruction. O.D. (Optical Density) has measured at 450 nM.^[@bib36]^

Alkaline phosphatase activity (ALP) and mineralization assay of BMCs
--------------------------------------------------------------------

At the end of the different treatments, mice were killed and BMCs from the femora were flushed out in osteoblast differentiation medium containing 10^−7^ M dexamethasone (bone marrow differentiation medium). Cells were seeded (2 × 10^6^ cells·per well) onto 12-well plates in bone marrow differentiation medium. BMCs were cultured for 21 days with a change of medium every 48 h. At the end of the experiment, ALP activity was measured at 405 nm and mineralized nodules were stained and quantified at 405 nm, as described for the mice calvarial osteoblast cells.^[@bib36]^

q-PCR
-----

SYBR green chemistry was for quantitative determination of various genes following an optimized protocol described before. The design of sense and antisense oligonucleotide primers was based on published cDNA sequences using the Universal ProbeLibrary (Roche Applied Sciences). Primer sequences are listed in [Table 1](#tbl1){ref-type="table"}. cDNA was synthesized with the RevertAid cDNA synthesis kit (Fermentas, Austin, TX, USA) using 2 *μ*g total RNA in 20 ml reaction volume. For Q-PCR, the cDNA was amplified using Light Cycler 480 (Roche Molecular Biochemicals, Indianapolis, IA, USA).^[@bib36]^

Oral bioavailability studies in Balb/c mice
-------------------------------------------

Adult female Balb/c mice were used for this study. The animals were given a 1 mg/kg bolus dose of CAFG by oral gavage and killed at 0, 15 min, 30 min,1 h, 2 h,3 h,4 h, 6 h, 8 h, 12 h and 24 h after treatment. Three animals were taken at each time point. Plasma was collected for the determination of CAFG levels. Data that represent the concentration--drug profile at 0 h time point were obtained from animals without any prior treatment. Sample processing was performed as described in previous study.^[@bib36]^

Studies on the *in vivo* expression of CAFG responsive genes
------------------------------------------------------------

Ten 1- to 2-day-old mice were divided into three equal groups and given a subcutaneous injection of either CAFG (1 mg/kg/day and 5 mg/kg/day dose in 50 ml) or equal volume of vehicle (normal saline) for 3 consecutive days. At the end of the treatment, pups were euthanized, and individual calvaria were harvested and cleaned of adherent tissue materials by gentle scrapping. Total RNA was isolated, and Q-PCR for ALP, Runx2 and COL1 was performed as described earlier.

3D trabecular and cortical micro-architecture analysis by *μ*-CT
----------------------------------------------------------------

Sky Scan 1076 microCT scanner (Sky Scan, Aartselaar, Belgium) was used to carry out *μ*-CT scanning of excised bones as described before. The bone samples were scanned at a resolution of 9 *μ*m and reconstruction was done using the Sky Scan Nrecon software. The X-ray source was set at 50 kV and 200 mA, with a pixel size of 9 *μ*m. A hundred projections were acquired over an angle arrange of 180 °C. CTanalyser (CTAn, Skyscan) software was used to draw ellipsoid contours in selected trabecular bone. Mean intercept length method was used to calculate trabecular bone volume, Tb.N and Tb.Sp. of the distal femoral epiphysis (covering secondary spongiosa and the secondary ossification center), proximal tibial and lumber 5 vertebrae. Tb.Th and SMI were calculated according to the method of Hildebrand and Ruegsegger. 3D parameters were based on analysis of a Marching cubes-type model with a rendered surface. CTVol software was used to create 3D model of the bones.^[@bib36]^

Fluorochrome labeling and bone histomorphometry
-----------------------------------------------

Cross-sections (50 *μ*m thickness) of periosteal regions of undecalcified diaphysis tibial bone of each mouse were obtained using an Isomet-Slow Speed Bone Cutter (Buehler, Lake Bluff, IL, USA). Images were captured using Leica-Qwin software (Leica Microsystems Inc., Buffalo Grove, IL, USA) and bone forming rate/bone surface (BFR/BS) and MAR were calculated. Tetracycline was injected 30 (20 mg/kg) days before termination of treatment, whereas calcien (20 mg/kg) 24 h before termination of treatment.^[@bib36]^ For TRAP histochemistry, femur bones were fixed in 4% formaldehyde and decalcified using EDTA solution. The bones were dehydrated, sectioned in 5 *μ*m thick size, deparaffined and TRAP staining was performed according to previously published protocol. Histological section of bone stained for TRAP activity was analyzed with bioquant software. Analysis of osteoclast number and osteoclast surface was performed according to standardized protocols of the American Society for Bone and Mineral.^[@bib38]^

Bone mechanical strength
------------------------

Bone mechanical strength was examined by compression test of lumber 5 vertebrae (L5) and breaking strength of femur with bone strength tester model TK 252C (Muromachi Kikai Co. Ltd., Tokyo, Japan), according to our previously published protocols.^[@bib36]^

Uterine histology and histomorphometry
--------------------------------------

The uterus of mice was weighed and fixed in 4% paraformaldehyde and dehydrated in ascending grades of isopropanol, cleared in xylene and embedded in paraffin wax using standard procedures. Transverse sections (5 *μ*m) were stained with hematoxylin and eosin and representative images were captured. Total uterine area, luminal area and luminal epithelial height were measured using Leica Qwin-Semiautomatic Image Analysis software (Leica).^[@bib36]^

Bone biochemical marker analysis
--------------------------------

Rat-MID OCN EIA (Immunodiagnostic Systems Limited, Boldon, UK) was performed using serum from treated and vehicle groups using manufacturer\'s protocol.^[@bib36]^

Osteoclast culture and TRAP Staining
------------------------------------

*In vitro* osteoclastogenesis was carried out using a standard protocol.^[@bib18],\ [@bib26],\ [@bib38]^ Mouse BMCs were flushed from femur bone using *α*-minimum essential medium eagle (*α*-MEM). Cells were seeded in T~25~ flask for overnight in osteoclast medium (*α*-MEM, 10% FCS, antibiotic, Earle\'s balanced salt solution, 10 ng/ml MCSF). After overnight incubation, non-adherent BMCs were seeded in 48-well plates at a density of 200 000 cells/well and cultured for 5--6 days in *α*-MEM containing 10% FCS, Earle\'s balanced salt solution, 50 ng/ml RANKL and 10 ng/ml MCSF and CAFG at 10nM concentrations. Medium was replaced after every 48 h, after 6 days of culture. Cells were washed with PBS and then fixed in 4% paraformaldehyde for staining and for RNA extraction using TRIZOL for analysis of TRAP and RANK mRNA levels by real-time PCR. Fixed cells were followed by TRAP staining using the standardized protocol.^[@bib38],\ [@bib26]^

Cell viability assay of CAFG
----------------------------

The cytotoxicity of CAFG on bone marrow osteoblast and chondrocytes was examined by MTT assay. Treated groups were differentiated into osteoblast cells and assess the cell proliferation and viability. Articular chondrocytes of newborn mice pups (1- to 2-day old) were treated with different concentrations of CAFG for 2 and 4 days. The cell viability/cytotoxicity was determined by using MTT assay (OD at 570 nm).

Alcian blue staining
--------------------

Mice articular chondrocyte cells are in pre-chondrocyte cells proliferative stage. At day 7 (columnar chondrocyte cells-highly proliferative stage) and day 14 (hypertrophic chondrocyte stage), chondrocytes culture cells were fixed with 4% paraformaldehyde for 15 min at room temperature and then incubated overnight with 0.1% alcian blue (pH 1--2). Excess stain was washed off with 3% glacial acetic acid with and pictures were taken. For quantitative analysis, bound alcian blue dye was extracted with 200 ml of 6 M guanidine HCl overnight at room temperature. The optical density of the extracted dye was measured at a wavelength of 630 nm.^[@bib39]^

Apoptosis assay
---------------

Mice calvarial osteoblast cells were cultured in 50--60% confluence by serum withdrawal for 3 h and treated with CAFG (10 nM) or without treatment for 24 h in *α*-MEM containing 0.5% FBS Annexin-V/PI staining for FACS analysis was carried out using Calbiochem Annexin-V-FITC Apoptosis Detection Kit (Calbiochem) according to the manufacturer\'s instructions.^[@bib36]^

Western blot analysis
---------------------

Mice calvarial osteoblast cells were grown to 80% confluency followed by exposure to compounds (CAFG) for different time periods. Cells were washed with cold phosphate-buffered saline (vehicle), and whole-cell lysates were prepared by the addition of lysis buffer Sigma-Aldrich containing a protease inhibitor mixture Sigma-Aldrich. 30--50 *μ*g of protein was loaded per lane and separated on a 10% polyacrylamide gel, followed by transfer to a PVDF membrane (Millipore, Billerica, MA, USA) by electroblotting. Membrane was blocked for nonspecific binding in 5% nonfat dry milk and followed by incubation with an primary antibody (Abcam) at 4 °C overnight. Membranes were washed and probed with a horseradish peroxidase-conjugated secondary antibody (Abcam) and visualized by an enhanced chemi-luminescence system (GE Healthcare Life Sciences, Lucknow, India) according to the manufacturer\'s instructions.^[@bib36]^

BMP2 ELISA
----------

For the quantitative determination of BMP2 concentration in cell culture supernates, osteoblast cells were seeded (20 × 10^3^ cells/well) in six-well plates. It contains CHO cell expressed recombinant human BMP2. Cell supernates were exposed to CAFG, Noggin and CAFG+Noggin and OD measured at 405 nm.^[@bib37]^

P-38 MAPK ELISA
---------------

For measuring total and phospho-p38 MAPK, osteoblast (20 × 10^3^ cells/well) were seeded in six-well plates. Cells were exposed to CAFG for different time intervals (0, 6, 12,24 h). Cells were lysed and proteins were quantified by Bradford kit (Cell Signaling Technologies) following the manufacturer\'s instruction. And OD measured at 405 nm.^[@bib37]^

Nuclear and cytosolic protein extraction experiment
---------------------------------------------------

Mice primary osteoblast cells were incubated in medium with CAFG, Noggin and CAFG+Noggin for 24 h. Nuclear and cytosolic protein were extracted by different lysis buffer using the manufacturer\'s protocol (CelLytic NuCLEAR Extraction Kit, Sigma-Aldrich). These extracted proteins were immunoblotted with *β*-catenin (Abcam) for nuclear translocation.^[@bib36]^

Immunocytochemistry
-------------------

Mice primary osteoblast cells were incubated in medium with CAFG, Noggin and CAFG+Noggin and were grown on Lab-Tek Chamber Slides (Nunc, Penfield, NY, USA) for 24 h. For immunocytochemistry, cells were fixed with 4% formaldehyde followed by permeabilization with 0.1% Triton X-100 and incubation in primary antibody (*β*-catenin) for overnight. Alexa Flour-488 (Invitrogen, Carlsbad, CA, USA) used as secondary antibody. Fluorescence was captured ( × 40) using fluorescent microscope (Eclipse 80i, Nikon, Tokyo, Japan), with the aid of appropriate filter (Excitation 495 nm and Emission 519 nm).^[@bib36]^

Luciferase reporter analysis
----------------------------

Runx2 luciferase vector and renilla were purchase from GeneCopoeia (Rockville, MD, USA). Primary mice calvarial osteoblast cells were plated onto 24-well plates. At 60--70% confluency, cells were transfected with Runx2 luciferase and renilla vector with 700 ng. After 24 h of post-transfection, cells were treated with or without CAFG in differentiating media. Lysates were then collected and luciferase intensity was determined using Dual assay luciferase kit (Promega Corporation, Madison, WI, USA).^[@bib40]^

TOPflash (TCF/LEF reporter plasmid)
-----------------------------------

For the detection of Wnt transcriptional activity, luciferase reporter-gene analysis was performed in HEK-293 cells with CAFG at the indicated concentrations. The cells were transfected with 1 mg TOP Flash or FOP Flash plasmid (Upstate Biotechnology, Lake Placid, NY, USA), 1 mg *β*-galactosidase vector (Promega, Madison, WI, USA) using Lipofectamine 2000 (Invitrogen). Luciferase and *β*-galactosidase activities were measured 48 h after transfection according to standard methods and were used to control transfection efficiency.^[@bib40]^

Grant from CSIR (BSC0201), ASTHI and Department of Biotechnology (DBT), Government of India are acknowledged. Scientist and In charge of Electron Microscopy for confocal imaging. The CDRI communication number is 184/2014/RT.
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BMC

:   bone marrow cell
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:   trabecular thickness
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Runx2

:   Runt-related transcription factor 2

RANKL

:   receptor activator of nuclear factor kappa-B ligand
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:   receptor activator of nuclear factor kappa-B
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:   quantitative real-time PCR

TRAP
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:   bone mineral density

MAPK

:   mitogen-activated protein kinase
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![CAFG has osteogenic but anti-estrogenic effect. (**a**) Structure of CAFG, caviunin and genistein (GEN). (**b**) *In vivo* dose determination of CAFG. CAFG stimulates osteoblastic gene expression at 1 mg/kg/day and 5 mg/kg/day doses. Values represent mean±S.E. \**P*\<0.05 and \*\*\**P*\<0.001 as compared with the control vehicle group. (**c**) Representation of 6 weeks treatment protocol with CAFG and standard controls. (**d**) 3D *μ*-CT images of trabecular micro-architecture of proximal tibial bone. (**e--i**) Analysis of trabecular micro-architecture of proximal tibia bone includes parameters BV/TV, Tb.Th, Tb.No, Tb.Sp. and SMI, respectively. All values are expressed as mean±S.E. \**P*\<0.05, \*\**P*\< 0.01, \*\*\**P*\<0.001 *versus* OVx; ^\#^*P*\<0.05, ^\#\#^*P*\<0.01, ^\#\#\#^*P*\<0.001 *versus* GEN 1 mg/kg/day, \**P*\<0.05, ^y^*P*\<0.01 *versus* CAFG 5 mg/kg/day and ^b^*P*\<0.01 *versus* GEN 5 mg/kg/day. (**j**) Transverse sections of tetracycline- and calcein-labeled tibia diaphysis from mice. Six weeks of treatment with CAFG significantly enhanced bone formation. (**k**) Serum OCN levels as measured at the end of experiment from various treatment groups. Data show that CAFG inhibits bone turnover in OVx mice. Values represent mean±S.E. \*\*\**P*\<0.001 *versus* OVx and ^\#^*P*\<0.05 *versus* GEN 1 mg/kg/day. (**l**) Uterine histology after treatment with CAFG, GEN, PTH and ALN from mice](cddis2014350f1){#fig1}

![CAFG enhances osteoblast mineralization through inhibitory effect of osteoclastogenesis. (**a**) *Ex vivo* experiments show that CAFG stimulates osteoblast proliferation and early differentiation assessed by ALP activity. Values represent mean±S.E. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001 *versus* OVx. ^\#^*P*\<0.05 *versus* GEN 1 mg/kg/day. (**b**) Oral supplementation of CAFG to OVx mice increased mineralized nodule formation in BMCs as assessed by Alizarin Red-S staining. Lower panel showed quantification of alizarin staining. Values represent mean±S.E. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\< 0.001 *versus* OVx; ^\#^*P*\<0.05, ^\#\#^*P*\<0.01, ^\#\#\#^*P*\<0.001 *versus* GEN 1 mg/kg/day. (**c**) Effect of CAFG on bone marrow cell proliferation of various treatment groups using BrdU incorporation cell proliferation assay. Values represent mean±S.E. of three independent experiments (*n*=3). \*\**P*\<0.01, \*\*\**P*\<0.001 when compared with OVx group. (**d--f**) Effect of CAFG on osteoclastogenesis and osteoblastogenesis marker in bone. CAFG enhanced mRNA levels of OPG (**d**), OCN, (**e**) expression but decrease mRNA levels of RANKL (**f**), TRAP and RANK (**g**) quantified with Q-PCR and normalized with GAPDH. Values represent mean±S.E. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\< 0.001 *versus* OVx; ^\#^*P*\<0.05, ^\#\#^*P*\<0.01,^\#\#\#^*P*\<0.001 *versus* GEN 1 mg/kg/day. (**h**) Representative images of TRAP staining in tibia bone. Quantitative estimation of osteoclast number (**i**) and osteoclast surface (**j**). Values represent mean±S.E. \*\**P*\<0.01 *versus* OVx](cddis2014350f2){#fig2}

![CAFG promotes proliferation and gene expression of chondrocytes. (**a**) Cytotoxicity analysis of CAFG at different concentrations at day 2 and 4 on chondrocytes. (**b**) Measurement of chondrogenesis in showing dose dependent and time dependent. Cells were fixed with 4% paraformaldehyde. After fixation, cell layers were stained with 0.5% alcian blue stain in 0.1 N HCl and rinsed, the extracted dye was quantified. Intensity of alcian blue staining measured at 630 nM. Data represent mean±S.E. \*\**P*\<0.01, \*\*\**P*\<0.001 compared with control. (**c**) Quantitative expression of chondrocyte-expressing genes by Q-PCR. The chondrocytes were cultured in different concentrations of CAFG for days 7 and 14. Values represent mean±S.E. from three independent experiments. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001 compared with control and the data normalized with internal control GAPDH. (**d**) Protein expression of protein specific to chondrocytes by western blot on day 14. The data normalized with internal control *β*-actin](cddis2014350f3){#fig3}

![CAFG promotes bone regeneration in the drill-hole site in Sham and OVx mice. (**a**) As shown 1 mm hole by drilling was generated in the mid-diaphysis region of the right femur bone. Defect region and intra-medulla region are clearly visible in representative two-dimensional image generated from *μ*-CT. (**b**) Represents confocal images (magnification= × 100) after calcein labeling shown in the drill-hole site of various groups and various time points 0, 11 and 21 days after injury without and with CAFG treatment. (**c**) Data show the quantification of the mean intensity of calcein labeling at the drill-hole site. Values represent mean±S.E. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001 compared with Sham and ^\#^*P*\<0.05, ^\#\#^*P*\<0.01, ^\#\#\#^*P*\<0.001 compared with OVx. Inter-dose comparison shows that values represent mean±S.E. \*\**P*\<0.01, 1 mg/kg is more significant than 5 mg/kg dose in Sham and in OVx (^\#\#^*P*\<0.01) 1 mg/kg is more significant than 5 mg/kg dose. (**d**) Representative 2D and 3D images generated by *μ*-CT showing bone healing in Sham and OVx mice following drill-hole injury. (**e**) Quantitative assessment of bone in Sham (control) group in the defect region. Data show BV/TV, Tb.No, Tb.Sp. and SMI. Values represent mean±S.E. \**P*\<0.05, \*\**P*\<0.01,\*\*\**P*\<0.001 compared with day 0. (**f**) Quantitative assessment of bone in OVx (control) group in the defect region. Data show BV/TV, Tb.No, Tb.Sp. and SMI. Values represent mean±S.E. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001 compared with day 0. (**g**) Expression of osteogenic and chondrogenic genes at the site of injury. Values represent mean±S.E. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001 compared with day 0. (**h**) Assessment of serum osteogenic marker osteocalcin at the end of healing process in bone. Values represent mean±S.E. \**P*\<0.05, \*\**P*\<0.01,\*\*\**P*\<0.001 compared with Sham and ^\#^*P*\<0.05, ^\#\#^*P*\<0.01, ^\#\#\#^*P*\<0.001 compared with OVx](cddis2014350f4){#fig4}

![CAFG promotes osteoblast differentiation through BMP2 signaling pathway. (**a**) CAFG (10 nM) treatment in mice calvarial osteoblast cells exerts anti-apoptotic effects in osteoblast. Using Becton Dickinson FACS and FL-H channel (Annexin-V) and FL2-H channel (PI) CAFG treatment inhibited apoptosis of osteoblast cells. Shown in the figure are representative dot plots. (**b**) Quantification of flow cytometry data is shown as a percent of total cells. Values represent mean±S.E. \**P*\<0.05 compared with control for early apoptosis. (**c**) ALP activity of CAFG after giving treatment with SB203580 inhibitor (10 *μ*M). Data represent mean±S.E. \**P*\<0.05, \*\**P*\<0.01 compared with control, ^\#\#\#^*P*\<0.001 compared with CAFG. (**d**) Mice calvarial osteoblast cells were exposed to CAFG at different time points and protein lysates were used to determine endogenous phospho-p38 MAPK activity after taking OD at 405 nm. Data represent mean±S.E. \*\*\**P*\<0.001 compared with control. (**e**) Western blot analysis of phoshorylated and unphosphorylated *P*-38 levels after 24 h treatment. (**f**) Western blot analysis of osteogenic gene BMP2 after giving CAFG treatment at different time points. (**g**) Relative mRNA expression of BMP2 after exogenous treatment with BMP2 (100 ng/ml) and BMP2 inhibitor noggin (50 ng/ml) at 24 h in mice calvarial osteoblast cells. (**h**) Western blot analysis after pretreatment of giving noggin treatment to mice calvarial osteoblast cells and then treatment of CAFG at 24 h. Data normalized by constitutive expressing gene *β*-actin. (**i**) Secreted BMP2 levels were assessed in conditioned media after treatment with CAFG by ELISA. Data represent mean±S.E. from three independent experiments. \**P*\<0.05, \*\*\**P*\<0.001 compared with control. (**j**) Relative mRNA expression of Smad1 and ALP after CAFG exogenous BMP2 (100ng/ml) and noggin (50 ng/ml) treatment at 24 h. (**k**) Activation effects of CAFG on BMP2 signaling pathway were tested using reporter construct *P*-Runx2-Luc. A full-length mouse Runx2 promoter construct was used to test this effect. Cells were transfected with construct for 24 h and treated with CAFG. Cell lysates were collected and luciferase activity was measured after 24 h. Normalized control Renilla was used and plotted as fold activity over untreated control. Data represent mean±S.E. from three independent experiments; \*\*\**P*\<0.001 compared with control. (**l**) Western blot analysis of various osteogenic genes phospho-Smad1, Smad1, Smad4, Runx2 after 24 h treatment in mice calvarial osteoblast cells. Data normalized by internal control *β*-actin. (**m**) Relative mRNA expression of BMP2 after pretreatment with CAFG and SB inhibitor (10 *μ*M). Data represent mean±S.E. from three independent experiments. \**P*\<0.05,\*\**P*\<0.01 compared with control](cddis2014350f5){#fig5}

![Effect of CAFG on Wnt signaling. (**a**) Relative mRNA expression of Wnt signaling genes after 24 h treatment on mice calvarial osteoblast cells with CAFG. Data represent mean±S.E. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001 compared with control. (**b**) Western blot analysis of Wnt3a, Dkk1, Sclerostin, Phospho-GSK3*β*, GSK3*β* and *β*-catenin after 24 h. Data normalized with internal control *β*-actin. (**c**) Quantitative assessment of proteins by densitometry. Data represent mean±S.E. \**P*\<0.05,\*\**P*\<0.01,\*\*\**P*\<0.001 compared with 0 h. (**d**) CAFG promotes *β*-catenin translocation after CAFG treatment in mice calvarial osteoblast cells at 24 h but translocation is inhibited by inhibitor noggin (50 ng/ml). Representative photomicrograph of subcellular localization of *β*-catenin was determined by immunofluorescence (magnification × 40) under control and treatment conditions from three independent experiments (*n*=3). (**e**) Nuclear and cytoplasmic extracts were prepared and *β*-catenin protein levels were detected by immune-blotting. Histone 3A was used as loading control for nuclear extract and *β*-actin was used as loading controls for cytoplasmic fraction. (**f**) This figure shows densitometry analysis of *β*-catenin levels from three independent blots. Values represent mean±S.E. of three independent experiments (*n*=3). \**P*\<0.05, \*\*\**P*\<0.001 compared with control. (**g**) Relative mRNA expression Wnt3a, *β*-catenin and BMP2 after giving CAFG (10 nM) and exogenous recombinant Dkk1 (100 ng/ml) for 24 h. Values are normalized with internal control GAPDH. \**P*\<0.05, \*\*\**P*\<0.001 compared with control. (**h**) Western blot analysis of above genes in the presence of CAFG and Dkk1. Internal control is *β*-actin. (**i**) Quantitative analysis of the proteins by densitometry. Values represent mean±S.E. of three independent experiments. \**P*\<0.05, \*\*\**P*\<0.001 compared with control. (**j**) Relative mRNA expression of Wnt3a, *β*-catenin and BMP2 after giving CAFG (10 nM) and FH535 (20 *μ*M) for 24 h.Values are normalized with internal control GAPDH. \**P*\<0.05, \*\*\**P*\<0.001 compared with control. (**k**) Western blot analysis of above genes in the presence of CAFG and FH535. Internal control is *β*-actin. (**l**) Densitometry analysis of above expressing protein. Values represent mean±S.E. of three independent experiments. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001 compared with control. (**m**) TOP FLASH activity of TCF/LEF in the presence of CAFG (10 nM) compared with control. *P*-WRE-Luc contained luciferase (Luc) enzyme tagged downstream of the TCF-binding element in responding to Wnt/*β*-catenin signaling. For the detection of Wnt transcriptional activity, luciferase reporter-gene analysis was performed in HEK-293 cells, osteoblast cells transfected with plasmid and cell lysates were collected for TOP Flash plasmid activity. Luciferase and β-galactosidase activities were measured 48 h after transfection according to standard methods and were used to control transfection efficiency, CAFG (10nM) was applied for 24 h. Data represent mean±S.E. \*\*\**P*\<0.001 compared with control](cddis2014350f6){#fig6}

![Effect of CAFG on osteoclast. (**a**) Representative photomicrograph ( × 40) shows that CAFG at 10 nM concentrations inhibits osteoclastogenesis from BMCs in the presence of M-CSF (10 ng/ml) and RANKL (50 ng/ml) in 5-day culture. (**b**) Quantitative representation of TRAP^+^ multinuclear and mononuclear cells after CAFG treatment. (**c**) Relative mRNA expression of TRAP and RANK determined by Q-PCR from the total RNA isolated from differentiated osteoclast normalized with GAPDH. (**d**) Western blot of TRAP and (**e**) densitometry analysis of expressing TRAP protein normalized with loading control *β*-actin. Values represent mean±S.E. of three independent experiments. \**P*\<0.05 compared with control](cddis2014350f7){#fig7}

![Schematic diagram outlining the novel molecular targets of CAFG leading to bone anabolic effects in osteogenic cells and fracture healing induced by BMP2/Wnt/*β*-catenin pathway. CAFG directly bind to BMP receptor and initiates Smad-dependent signaling. After phosphorylation of Smad1, Smad4 directly binds to phospho-Smad1 and translocates to the nucleolus where they initiate transcription factor RunX2. Besides this CAFG binds to Wnt-frizzled receptor and activates *β*-catenin translocation to the nucleolus where it binds to TCF/LEF complex and promotes osteoblastogenesis. CAFG increases OPG levels to inhibit osteoclastogenesis. The same pathway further initiates intramembranous ossification at the site of injury to repair bone](cddis2014350f8){#fig8}

###### Effects of various treatment groups for 6 weeks on different bone parameters of osteopenic mice

  **Parameters**                                               **Sham+veh**       **OVx+veh**        **OVx+GEN**     **OVx+GEN**     **OVx+CAFG**      **OVx+CAFG**      **OVx+PTH**        **OVx+ALN**
  ------------------------------------------------------------ ------------------ ------------------ --------------- --------------- ----------------- ----------------- ------------------ -----------------
                                                               **(gum-acacia)**   **(gum-acacia)**   **(1 mg/kg)**   **(5 mg/kg)**   **(1 mg/kg)**     **(5 mg/kg)**     **(40 *μ*g/kg)**   **(3 mg/kg)**
  *Biomechanical strength of femur*                                                                                                                                                         
   Stiffness (N/mm)                                            75.4±10.1^c^       19.6±2.2           41.5±11.4^a^    56.8±9.5^a^     69.9±6.7^c^       52.5±3.9^a^       52.8±2.9^a^        47.1±5.6^a^
   Energy (mj)                                                 5.86±0.83^b^       2.22±0.25          4.56±0.22^b^    6.22±0.57^b^    6.94±0.83^b^      6.8±0.32^b^       6.6±0.36^b^        5.78±1.43^b^
                                                                                                                                                                                             
  *Biomechanical strength of lumber-5 (L-5) vertebrae*                                                                                                                                      
   Stiffness (N/mm)                                            324.5±38.1^b^      163.9±11           314.5±35.4^b^   320.3±25.3^b^   344.2±28.3^b^     332.5±20.6^b^     346.3±20^b^        345.8±18.7^b^
   Energy (mj)                                                 387.3±23^c,+^      229.5±12.4         299.6±25.1      324.2±18.1^a^   411.3±27.9^c,+^   406.4±18.1^c,+^   396.4±12.6^c,+^    418.5±10.5^c,+^
                                                                                                                                                                                             
  *Dynamic histomorphometric measurement at femur diaphysis*                                                                                                                                
   MAR (*μ*m/day)                                              0.27±0.027^b^      0.15±0.012         0.22±0.02       0.24±0.014^a^   0.26±0.016^a^     0.24±0.03^c^      0.36±0.013^c^      0.20±0.010
   BFR/BS (*μ*m^3^μm^2^/day)                                   0.29±0.02^c^       0.10±0.01          0.20±0.02^b^    0.26±0.01^c^    0.29±0.008^c^     0.25±0.02^c^      0.33±0.01^c^       0.16±0.009
                                                                                                                                                                                             
  *Uterine Parameters*                                                                                                                                                                      
   Uterine wt. (mg)                                            0.13±0.009         0.02±0.003^z^      0.05±0.008^z^   0.03±0.004^z^   0.033±0.004^z^    0.04±0.003^z^     0.028±0.003^z^     0.02±0.003^z^
   Total uterine area (*μ*m^2^)                                5883.6±134.3       783.4±20.6^z^      959.4±28.8^z^   927.8±44.7^z^   799±26.7^z^       865.2±20.3^z^     865.1±39.05^z^     881.8±65.1^z^
   Luminal area (*μ*m^2^)                                      507.4±5.9          62.6±3.9^z^        76±2.6^z^       70.3±5.2^z^     61.3±5.7^z^       66.6±3.2^z^       65±8.6^z^          68±1.5^z^
   Luminal epithelial cell height (*μ*m)                       1.51±0.09          0.58±0.02^z^       0.77±0.03^z^    0.65±0.07^z^    0.58±0.03^z^      0.61±0.04^z^      0.58±0.04^z^       0.64±0.04^z^

^a^*P*\<0.05, ^b^*P*\<0.01, ^c^*P*\<0.001 *versus* OVx; ^z^*P*\<0.001 *versus* Sham, ^+^*P*\<0.05, *versus* GEN 1 mg

###### Micro-CT analysis and mechanical testing of intact femurs from Sham and OVx mice at 6 weeks post ovary surgery

  **Parameters**                          **Sham**     **OVx**
  --------------------------------------- ------------ ----------------------
  *Micro-CT analysis of distal femur*                  
  BV/TV (%)                               3.80±0.29    1.91±0.21**\*\*\***
  Tb.Th (mm)                              0.06±.002    0.04±0.005**\*\***
  Tb.N (m/m)                              2.28±0.14    1.17±0.16**\*\*\***
  Tb.Sp. (mm)                             0.39±0.012   0.58±0.02**\*\*\***
  SMI                                     1.63±0.04    2.42±0.10**\*\*\***
  Conn.Dn (1/mm^3^)                       70.32±3.35   36.13±3.43**\*\*\***
                                                        
  *Micro-CT analysis of femoral shaft*                 
  BV/TV (%)                               52.36±0.51   47.92±1.28**\***
  T.Ar (mm^2^)                            1.76±0.04    1.64±0.12**\***
  Cs.Th (mm)                              0.24±0.0     0.18±0.01 **\***
  B.Ar (mm^2^)                            0.86±0.02    0.70±0.06**\***
  B.Pm (mm)                               8.79±0.25    7.27±0.40**\*\***
                                                        
  *Mechanical testing of femoral shaft*                
  Maximum power (N)                       32.16±2.89   20.66±4.07**\***
  Energy (mJ)                             5.76±0.68    3.11±0.30**\***
  Stiffness (N/mm)                        58.51±2.26   45.76±3.11**\*\***

*N*=6

**\****P*\<0.05, **\*\****P*\<0.01, **\*\*\****P*\<0.001 for significant difference between the Sham and OVx groups
